Trial Profile

suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary)
Indications COVID 2019 infections; COVID-19 pneumonia; COVID-19 respiratory infection; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms SAVE

Most Recent Events

12 Jul 2023 Status changed from active, no longer recruiting to completed.
24 Jun 2023 Results (n=153) assessing to identify protein biomarkers and endotypes for COVID-19 severity and evaluate their reproducibility in an independent cohort, published in the Respiratory Medicine.
11 Jan 2023 Planned End Date changed from 15 Oct 2022 to 28 Feb 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com